medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 2

<< Back Next >>

Ann Hepatol 2008; 7 (2)

The natural course of HCV infection and the need for treatment

Bruno S, Facciotto C

Language: English
References: 54
Page: 114-119
PDF size: 119.37 Kb.


Text Extraction

Nowadays, hepatitis C infection has been identified as the main cause of chronic liver disease, including cirrhosis and hepatocellular carcinoma in Western Countries. However, despite its large diffusion (with more than 150 million of people infected world-wide), the lack of symptoms during the acute phase, together with the indolent course of the disease over time, hampers the difficulties to assess the natural history of the disease, which still remains an interesting clinical dilemma.. This complexity can also be argued from the large heterogeneity of disease complication’s rate observed when different methodological approaches were used (retrospective cohort studies, prospective cohort studies, retrospective-prospective cohort studies).
Moreover, the progression of the disease could also be dramatically affected by many variables related to the host, the virus and the environment. Finally, in the last few years, the long–term outcome of the infected subjects, has been deeply modified by the use of efficacy antiviral therapy, as shown by the better survival observed in patients who had achieved a sustained virological response after interferon treatment.


REFERENCES

  1. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002; 36(5): S3-S15.

  2. Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, Neal KR, et al. The natural history of hepatitis C with sever hepatic fibrosis. J Hepatol 2007; 47: 37-45.

  3. Afdhal HN. The natural history of hepatitis C. Seminars in Liver Disease 2004; 24(S2): 3-8.

  4. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.

  5. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-66.

  6. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow up of chronic pot-transfusion hepatitis. Hepatology 1991; 14: 969-74.

  7. Koretz RL, Abbey H, Coleman E, Gitnick G. NANB post-transfusion hepatitis: looking back on the second decade. Ann Intern Med 1993; 119: 110-5.

  8. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globuline. N Engl J Med 1999; 340: 1228-33.

  9. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U, for the East German Hepatitis C Study Group. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-6.

  10. Wiese M, Grungreiff K, Guthoff W, Lafraenz M, Oesen U, Porst H for the East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 25-year multicenter study. J Hepatol 2005; (43): 590-598.

  11. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.

  12. Seef L, Hollinger B, Alter HJ, Wright EC, Cain CMB, Buskell ZJ, Ishak KG, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: a national heart, lung and blood institute collaborative study. Hepatology 2001; 33: 455-63.

  13. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-7.

  14. Seef L, Miller R, Rabkin C, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-11.

  15. Thomas DL, Astemborsky J, Rai RM, Anania FA, Shaeffer M, Galai N, Nolt H, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 33: 455-63.

  16. Rossi S, De Filippi F, Saibeni S, Persico M, Bollani S, Camera A, Rizzolo L, et al. A 15-Yr prospective histological follow-up study in patients with persistently normal aminotransferase levels (PNAL) carrying HCV infection. Am J Gastroenterol 2007; 102(11): 2604-6 (Letter to the editor).

  17. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, et al. Natural history of hepatitis C virus carrier with persistently normal aminotransferase levels. Gastroenterol 2000; 118: 760-4.

  18. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hep 2002; 9: 71-4.

  19. Kobayshi M, Tanaka E, Sodeyama T, Urushilara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotype 1 and 2 hepatitis C viruses. Hepatology 2001; 34: 764-7.

  20. Poynard T, Bedossa P, Opolon P for OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.

  21. Farci P, Shimoda A, Coiana A, Diaz G, Meldolder JC, Strazzera A, Chien DY, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasi-species. Science 2000; 288: 339-44.

  22. Minola E, Prati D, Suter F, Maggiolo F, Capriolo F, Sonzogni A, Fraquelli M, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99(12): 4588-91.

  23. Spengler U, Rockson JK. Hepatitis C in the patient with human immunodeficiency virus infection. J Hepatol 1998; 29: 1023-30.

  24. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globuline. N Engl J Med 1994; 331: 1607-11.

  25. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43(1): 64-71.

  26. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, Modola G, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30(6): 984-9.

  27. Bonkowsky H, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.

  28. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon therapy: a multicententer, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-38.

  29. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27(4): 914-9.

  30. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  31. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-9.

  32. Sangiovanni A, Prati G, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.

  33. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.

  34. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58: 348-351.

  35. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-8.

  36. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46(5): 1350-6.

  37. Nishise Y, Saito T, Sugahara K, Ito JI, Togashi H, Nagano-Fujii M, Hotta H, et al. Risk of hepatocellular carcinoma and secondary structure of hepatitis C Virus NS3 protein amino-terminus, in patients infected with HCV subtype 1b. JID 2007; 196: 1006-9.

  38. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.

  39. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580.

  40. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903.

  41. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, et al. Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-488.

  42. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61.

  43. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, et al. Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114.

  44. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689-698.

  45. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45(3): 579-87.

  46. Veldt BJ, Heathcote JE, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.

  47. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44(6): 1675-84.

  48. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130(1): 231-64.

  49. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343(23): 1673-80.

  50. Marrache F, Consigny Y, Ripault MP, Cazals-Hatem D, Martinot M, Boyer N, Degott C, et al. Safety and efficacy of Peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005; 12: 421-8.

  51. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358(9286): 958-65.

  52. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. PEGASYS International Study Group. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-55.

  53. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  54. Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, et al. Peginterferon-alfa2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis; a multicentre randomized trial comparing two doses of peginterferon-alfa2b. J Viral Hepat 2006; 13: 811-20.




2020     |     www.medigraphic.com